23 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22743 | Metastatic hormono-sensitive prostate carcinoma | Thierry Gil | prostate | Unicancer | PEACE EORTC 1201 GETUG-AFU 21 | Trial closed for recruitment | A Prospective randomized phase III study of Androgen deprivation therapy with or without local radiotherapy with or without Abiraterone Acetate and Prednisone in patients with metastatic hormone-naïve prostate cancer | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22687 | Metastatic | François-Xavier Otte | prostate | UZ-Gent | PEACE V - STORM | Trial open for recruitment | PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22638 | cN1/cT3-T4 | François-Xavier Otte | prostate | EORTC | Pegasus | Trial closed for recruitment | Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG. Pegasus | accueil.cons.radiotherapie@hubruxelles.be | 3 | 3 | |
| 22934 | - The treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study - Patients with histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases |
Carlos Artigas Guix | prostate | Bayer | REASSURE | Trial closed for recruitment | REASSURE, Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation (Bayer 16913) | carlos.artigas@hubruxelles.be | 4 | 4 | |
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 29059 | Spyridon Sideris | prostate | Pfizer | Talapro-3 | Trial closed for recruitment | Talapro-3: A Phase 3, Randomized, Double-Blind, Study Of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide In Men With Ddr Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 22708 | *Must have received at least one NAAD(enzalutamide or abiraterone). *1 or 2 prior treatment with taxane *Progressive disease |
Carlos Artigas Guix | prostate | Endocyte | VISION | Trial closed | VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | carlos.artigas@hubruxelles.be | 3 | 3 |